Brokerage Firm Rating on Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX) : 19 analysts are covering Boston Scientific Corporation (BSX) and their average rating on the stock is 1.55, which is read as a Buy. 12 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Boston Scientific Corporation (BSX) also receives 3 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Boston Scientific Corporation (BSX) : Average target price received by Boston Scientific Corporation (BSX) is $26.08 with an expected standard deviation of $2.99. The most aggressive target on the stock is $30, whereas the most downbeat target is $20. 18 financial analysts are currently covering the stock.


For the current week, the company shares have a recommendation consensus of Buy. Boston Scientific Corporation (NYSE:BSX): The stock opened at $23.90 on Thursday but the bulls could not build on the opening and the stock topped out at $23.95 for the day. The stock traded down to $23.74 during the day, due to lack of any buying support eventually closed down at $23.86 with a loss of -0.08% for the day. The stock had closed at $23.88 on the previous day. The total traded volume was 6,190,066 shares.

In a related news, Mahoney Michael F, director officer (President & CEO) of Boston Scientific Corp, unloaded 44,400 shares at an average price of $24.44 on August 1, 2016. The total amount of the transaction was worth $1,085,136, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.